Company Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.
The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases.
In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050.
Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Apr 8, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 136 |
| CEO | Dr. Jasbir S. Seehra Ph.D. |
Contact Details
Address: 1050 Waltham Street, Suite 302 Lexington, Massachusetts 02421 United States | |
| Phone | 617-314-6297 |
| Website | kerostx.com |
Stock Details
| Ticker Symbol | KROS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001664710 |
| CUSIP Number | 492327101 |
| ISIN Number | US4923271013 |
| Employer ID | 81-1173868 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jasbir S. Seehra Ph.D. | President, Chief Executive Officer, Treasurer, and Director |
| Christopher Rovaldi M.Sc. | Chief Operating Officer |
| Keith C. Regnante MBA | Chief Financial Officer |
| Esther Cho J.D. | Senior Vice President, General Counsel and Secretary |
| Robin Wagner | Senior Vice President of Human Resources |
| John Oram M.B.A. | Senior Vice President of Program and Portfolio Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| May 3, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Apr 17, 2024 | ARS | Filing |
| Apr 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 14, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |
| Mar 5, 2024 | 8-K | Current Report |